Stories Category Subscribe to RSS Feed

Case report: Tramadol-associated respiratory depression in CYP2D6 ultrarapid metabolizer

Published: Mar 1st, 2015

Tramadol is metabolized through numerous pathways, including oxidation by the CYP2D6 enzyme to O-desmethyltramadol, which is primarily responsible for its analgesic effects. Although it has been documented that CYP2D6 genetic […]

JAMA: Vincristine peripheral neuropathy linked to CEP72 variability

Published: Feb 25th, 2015

Vincristine is a widely used cytotoxic agent for cancer treatment in adults and children. A significant portion of patients treated with vincristine experience dose-limiting neuropathies including pain, sensory, and motor […]

New antifungal guidelines highlight CYP2C19 testing for voriconazole

Published: Jan 15th, 2015

Voriconazole is an azole antifungal used to treat serious fungal infections. It is metabolized primarily by the CYP2C19 enzyme and genetic polymorphisms in the CYP2C19 gene account for a large portion […]

Warfarin: Inclusion of genotypes important for African Americans leads to better dose prediction

Published: Dec 15th, 2014

Warfarin is used widely to prevent thromboembolic events. Numerous studies have demonstrated that CYP2C9 and VKORC1 genotypes influence warfarin dosage requirements. However, the Clarification of Optimal Anticoagulation through Genetics (COAG) […]

DPYD and 5-fluorouracil toxicity: Results of largest study to date support association

Published: Dec 1st, 2014

Use of the antimetabolite 5-fluorouracil (5–FU) is associated with variability in both efficacy and toxicity. Dihydropyrimidine dehydrogenase (DPD) is the rate-limiting catabolic enzyme for 5–FU and eliminates approximately 85% of […]

Clinical use of CYP2D6–codeine guidelines

Published: Nov 15th, 2014

The analgesic properties of codeine result from its activation by the CYP2D6 enzyme to morphine, which has 200-fold greater affinity for opioid receptors. The metabolism and activity of some other […]

Escitalopram, citalopram: Are higher doses needed in CYP2C19 ultrarapid metabolizers?

Published: Oct 31st, 2014

Miguel Ramos, PharmD Citalopram and escitalopram are selective serotonin reuptake inhibitors commonly used to treat depression, anxiety, and related disorders. Both agents are metabolized primarily by CYP2C19, a polymorphic enzyme […]

Limitations of pharmacogenomic data in FDA-approved drug labels

Published: Oct 15th, 2014

Pharmacogenomic biomarker information is included in Food and Drug Administration (FDA)-approved product labeling, or prescribing information, for over 100 drugs. This information may be used to support the clinical use […]

Pharmacists play key roles in clinical pharmacogenomics

Published: Sep 30th, 2014

The role of the pharmacist in implementing pharmacogenomic data into clinical care is increasingly being recognized. Pharmacists are uniquely qualified to provide input and leadership in this area due to […]

New meta-analysis shows 50 percent decrease in serious bleeding with genotype-guided warfarin

Published: Sep 15th, 2014

Warfarin is used widely to prevent thromboembolic events. Although genetic variability in CYP2C9 and VKORC1 have been shown to influence warfarin dosage requirements, studies investigating the impact of this variability […]